Stock events for REGENXBIO, Inc. (RGNX)
REGENXBIO's stock decreased by 26.7% since the beginning of 2026, trading at $10.55 as of May 9, 2026. The FDA placed clinical holds on RGX-111 and RGX-121 due to a CNS tumor discovery, causing a 17.8% stock drop. The company reported Q4 2025 EPS of ($1.30) and full-year 2025 revenue of $170 million. Topline results from the pivotal trial of RGX-202 are expected in early Q2 2026.
Demand Seasonality affecting REGENXBIO, Inc.’s stock price
Demand seasonality is not directly applicable to REGENXBIO, as its revenue is driven by clinical trial milestones, regulatory approvals, and partnerships, rather than seasonal consumer purchasing patterns. Demand for potential future commercial products will be driven by medical need and regulatory approval, not seasonal fluctuations.
Overview of REGENXBIO, Inc.’s business
REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapy, operating within the Healthcare sector. It develops, commercializes, and licenses AAV gene therapies using its NAV® Technology Platform, which includes rights to over 100 novel AAV vectors. Key product candidates include ABBV-RGX-314 for retinal diseases, RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and RGX-111 for Hurler syndrome.
RGNX’s Geographic footprint
REGENXBIO Inc. is headquartered in Rockville, Maryland, United States. The company has a global presence with clinical trial sites in North America, Europe, and Asia.
RGNX Corporate Image Assessment
REGENXBIO's brand reputation was negatively impacted by the FDA clinical holds on RGX-111 and RGX-121, following the discovery of a CNS tumor in a participant. This led to concerns about safety and a drop in stock price, as well as securities class action lawsuits alleging the company failed to disclose known safety risks associated with RGX-111.
Ownership
REGENXBIO Inc. is primarily owned by institutional shareholders (79.71%), followed by Regenxbio insiders (24.95%). As of May 7, 2026, 175 institutional owners held 40,010,208 shares. Major institutional owners include BlackRock, Inc., Redmile Group, LLC, and JPMorgan Chase & Co. The largest individual shareholder is Allan M. Fox, owning 6.91 million shares (13.38%).
Ask Our Expert AI Analyst
Price Chart
$7.01
